Paloma Partners’s Corvus Pharmaceuticals CRVS Stock Holding History

Paloma Partners’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-39,787	Closed	-$149K	–	2010
2019 Q2	$149K	Buy	+39,787	New	+$156K	﹤0.01%	1589
2019 Q1	–	Sell	-15,900	Closed	-$58K	–	1724
2018 Q4	$58K	Buy	+15,900	New	+$108K	﹤0.01%	1158

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Paloma Partners's CRVS Position: Q3 2019 in Review

Paloma Partners sold out of Corvus Pharmaceuticals (CRVS) in Q3 2019, closing a stake of 39,787 shares — an estimated $149K sold.

Paloma Partners first reported a position in CRVS in Q4 2018 and held it in 2 quarters. The position peaked at $149K in Q2 2019. 35 funds tracked by Wall St. Rank hold CRVS as of Q3 2019.

Paloma Partners reported no remaining Corvus Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Paloma Partners sold 39,787 Corvus Pharmaceuticals shares in Q3 2019, an estimated $149K.
Paloma Partners first reported a position in Corvus Pharmaceuticals in Q4 2018 and held it in 2 quarters.
Paloma Partners's Corvus Pharmaceuticals position peaked at $149K in Q2 2019.
35 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2019.

Based on Paloma Partners's 13F filing for Q3 2019, filed 14 Nov 2019.